HBC Hofseth Biocare

Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION

Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION

Christoph Baldegger, primary insider and member of the Board of Directors in Hofseth BioCare ASA ("HBC") holds 1,500,000 shares personally and has held 1,747,976 shares indirectly through the Bonafide fund. Redemption of the fund has led to transfer of his indirect holdings to his personal account, and hence Mr. Baldegger now personally holds 3,247,976 shares and zero indirect ownership in HBC, equal to approximately 0.82 % of the total outstanding A-shares with voting rights.

For further information, contact:

Jon Olav Ødegård, CEO of Hofseth BioCare ASA

Phone:

E-mail:

This information is subject to the disclosure requirements in the Market Abuse Regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.



EN
20/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hofseth Biocare

 PRESS RELEASE

Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2025

Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2025 The Annual General Meeting of Hofseth BioCare ASA for 2025 will be held at the company's premises at Keiser Wilhelms gate 24, 6003 Ålesund, on 23 May 2025 at 13:00 CET. The notice of the Annual General Meeting is attached. For further information, please contact: Jon Olav Ødegård, CEO of Hofseth BioCare ASA Phone: E-mail: About Hofseth BioCare ASA: Hofseth BioCare is a Norwegian consumer and pet health company founded on the core values of sustainability, optimal utilization of natural resources and full traceability. It upc...

 PRESS RELEASE

Hofseth Biocare ASA: HBC ANNUAL REPORT 2024

Hofseth Biocare ASA: HBC ANNUAL REPORT 2024 The Board of Directors of Hofseth BioCare ASA ("HBC") has approved the financial statements for 2024, and HBC has today published the Annual Report and Sustainability Report for 2024. Please find the Annual Report and ESG Report attached. For further information, please contact:Jon Olav Ødegård, CEO of Hofseth BioCare ASAPhone: E-mail: About Hofseth BioCare ASA:Hofseth BioCare is a Norwegian consumer and pet health company founded on the core values of sustainability, optimal utilization of natural resources and full traceability. It upcycle...

 PRESS RELEASE

Hofseth Biocare ASA: CONTEMPLATING UNSECURED BOND ISSUANCE

Hofseth Biocare ASA: CONTEMPLATING UNSECURED BOND ISSUANCE Hofseth BioCare ASA has retained Novum Asset Management AG to investigate the potential issuance of CHF-denominated unsecured bonds with an expected volume of up to CHF 8 million, towards investors in Switzerland and Liechtenstein. Further, the Company may contact investors in Norway directly. The Company targets a tenor of three years for the Bonds. Further information about any issuance of Bonds, and the terms and conditions of such bonds, will be given in due course. For further information, please contact:Jon Olav Ødegård, CE...

 PRESS RELEASE

Hofseth Biocare ASA: HBC ACCELERATES IN HUMAN HEALTH AND PET NUTRITION...

Hofseth Biocare ASA: HBC ACCELERATES IN HUMAN HEALTH AND PET NUTRITION THROUGH A STRATEGIC PARTNERSHIP WITH SYMRISE TO BUILD OUT BERKÅK, TRIPLING THE MANUFACTURING CAPACITY OF THE GROUP HBC will accelerate its manufacturing scale and market reach with the construction of a second enzymatic hydrolysis plant in Berkåk, Norway. Symrise will support the financing of the project through a EUR 5m loan. The partnership ideally complements both HBC and Symrise’s current portfolio with science-led, clinically proven marine ingredients for Consumer Health. HBC have also signed an exclusive distributi...

 PRESS RELEASE

Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION

Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION Christoph Baldegger, primary insider and member of the Board of Directors in Hofseth BioCare ASA ("HBC") holds 1,500,000 shares personally and has held 1,747,976 shares indirectly through the Bonafide fund. Redemption of the fund has led to transfer of his indirect holdings to his personal account, and hence Mr. Baldegger now personally holds 3,247,976 shares and zero indirect ownership in HBC, equal to approximately 0.82 % of the total outstanding A-shares with voting rights. For further information, contact:Jon Olav Ødegård, CEO of Hofset...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch